|
WO2020264379A1
|
|
Markers for the diagnosis of prostate cancer
|
|
US2020292548A1
|
|
Markers for the diagnosis of biochemical recurrence in prostate cancer
|
|
WO2020097380A1
|
|
Methods for treating parkinson's disease
|
|
US2020176118A1
|
|
Methods and systems for septic shock risk assessment
|
|
US2020190589A1
|
|
Use of markers in the diagnosis and treatment of lupus
|
|
WO2020081601A1
|
|
Methods of treating pancreatic cancer using coenzyme q10
|
|
AU2019339896A1
|
|
Methods of treating cancer by inhibiting ubiquitin conjugating enzyme E2 K (UBE2K)
|
|
AU2019301756A1
|
|
Methods for differentiating benign prostatic hyperplasia from prostate cancer
|
|
CN110769818A
|
|
Use of coenzyme Q10 preparation for treating and preventing epidermolysis bullosa
|
|
US2018135129A1
|
|
Methods for treating parkinson's disease
|
|
WO2018085441A1
|
|
Filamin b binding proteins and uses thereof
|
|
WO2018085431A1
|
|
Filamin a binding proteins and uses thereof
|
|
US2018021270A1
|
|
Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
|
|
EP3490677A1
|
|
Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
|
|
AU2017278261A1
|
|
Systems and methods for patient stratification and identification of potential biomarkers
|
|
AU2017278257A1
|
|
Preventing or mitigating chemotherapy induced alopecia using vitamin D
|
|
WO2017161205A1
|
|
Methods for the treatment of cancer using coenzyme q10 and fatty acid metabolism inhibitors
|
|
US2017189350A1
|
|
Methods of treatment of temozolomide-resistant glioma using coenzyme q10
|
|
AU2016222326A1
|
|
Topical formulations having enhanced bioavailability
|
|
CN107949372A
|
|
Enolase 1（Eno1）Composition and application thereof
|
